Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Sarcopenia | Research

Branched-chain amino acids supplementation improves liver frailty index in frail compensated cirrhotic patients: a randomized controlled trial

Authors: Sith Siramolpiwat, Nisakorn Limthanetkul, Bubpha Pornthisarn, Ratha-korn Vilaichone, Soonthorn Chonprasertsuk, Patommatat Bhanthumkomol, Pongjarat Nunanan, Navapan Issariyakulkarn

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Physical frailty is related with morbidity and mortality in patients with cirrhosis. Currently, there is no approved treatment of frailty in these patients. Here, we evaluated the efficacy of 16 weeks branched-chain amino acids (BCAA) supplementation on frailty in frail compensated cirrhotic patients.

Methods

After a 4-week run-in period consisted of dietary and exercise counseling, compensated cirrhotic patients with frailty, defined by liver frailty index (LFI)≥4.5, were randomly assigned (1:1) to BCAA or control group. The BCAA group received twice daily BCAAs supplementation (210 kcal, protein 13.5 g, BCAA 2.03 g) for 16 weeks. The primary outcome was frailty reversion. The secondary outcomes were changes in biochemistries, body composition evaluated by bioelectrical impedance analysis, and quality of life (QoL).

Results

54 patients were prospectively enrolled (age 65.5 ± 9.9 years, 51.9% female, Child-Pugh A/B 68.5%/31.5%, MELD 10.3 ± 3.1). Baseline characteristics were similar between both groups. At week 16, BCAA group had a significant improvement in LFI (-0.36 ± 0.3 vs. -0.15 ± 0.28, P = 0.01), BMI (+ 0.51 ± 1.19 vs. -0.49 ± 1.89 kg/m2, P = 0.03), and serum albumin (+ 0.26 ± 0.27 vs. +0.06 ± 0.3 g/dl, P = 0.01). The proportion of frailty reversion at week 16 was significantly higher in BCAA group (36% vs. 0%, P < 0.001). Compared with baseline, BCAA group had a significant increase in skeletal muscle index (7.5 ± 1.6 to 7.8 ± 1.5 kg/m2, P = 0.03). Regarding the QoL, only the BCAA group had a significant improvement in all 4 domains of physical component score of the SF-36 questionnaire.

Conclusions

A 16-week BCAA supplementation improved frailty in frail compensated cirrhotic patients. In addition, this intervention resulted in an improvement of muscle mass and physical domain of QoL in these patients.

Trial registration

This study was registered with Thai Clinical Trial Registry (TCTR20210928001; https://​www.​thaiclinicaltria​ls.​org/​#).
Literature
1.
Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, Frailty, and Sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the study of Liver Diseases. Hepatology. 2021;74(3):1611–44.CrossRefPubMed
2.
Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75(Suppl 1):147–S62.CrossRef
3.
Cron DC, Friedman JF, Winder GS, Thelen AE, Derck JE, Fakhoury JW, Gerebics AD, Englesbe MJ, Sonnenday CJ. Depression and Frailty in patients with end-stage liver disease referred for transplant evaluation. Am J Transplant. 2016;16(6):1805–11.CrossRefPubMed
4.
Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, Ma M, Bailey RJ, Jayakumar S, Burak KW, et al. A Rapid Bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical Frailty Scale. Am J Gastroenterol. 2016;111(12):1759–67.CrossRefPubMed
5.
Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, Feng S. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66(2):564–74.CrossRefPubMed
6.
Lai JC, Rahimi RS, Verna EC, Kappus MR, Dunn MA, McAdams-DeMarco M, Haugen CE, Volk ML, Duarte-Rojo A, Ganger DR, et al. Frailty Associated with Waitlist Mortality Independent of Ascites and hepatic encephalopathy in a Multicenter Study. Gastroenterology. 2019;156(6):1675–82.CrossRefPubMed
7.
Dunn MA, Josbeno DA, Tevar AD, Rachakonda V, Ganesh SR, Schmotzer AR, Kallenborn EA, Behari J, Landsittel DP, DiMartini AF, et al. Frailty as tested by Gait Speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol. 2016;111(12):1768–75.CrossRefPubMed
8.
Siramolpiwat S, Kiattikunrat K, Soontararatpong R, Pornthisarn B, Vilaichone RK, Chonprasertsuk S, Bhanthumkomol P, Nunanun P, Issariyakulkarn N. Frailty as tested by the liver Frailty Index is associated with decompensation and unplanned hospitalization in patients with compensated cirrhosis. Scand J Gastroenterol. 2021;56(10):1210–9.CrossRefPubMed
9.
Tapper EB, Derstine B, Baki J, Su GL. Bedside Measures of Frailty and cognitive function correlate with Sarcopenia in patients with cirrhosis. Dig Dis Sci. 2019;64(12):3652–9.CrossRefPubMed
10.
Lai JC, Dodge JL, Kappus MR, Dunn MA, Volk ML, Duarte-Rojo A, Ganger DR, Rahimi RS, McCulloch CE, Haugen CE, et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020;73(3):575–81.CrossRefPubMedPubMedCentral
11.
Lo EKK, Felicianna, Xu JH, Zhan Q, Zeng Z, El-Nezami H. The Emerging Role of Branched-Chain Amino Acids in Liver Diseases. Biomedicines. 2022;10(6).
12.
Okuno M, Moriwaki H, Kato M, Muto Y, Kojima S. Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. Biochem Biophys Res Commun. 1995;214(3):1045–50.CrossRefPubMed
13.
Liver EAftSot. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93.CrossRef
14.
Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R, Italian BSG. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792–801.CrossRefPubMed
15.
Hernandez-Conde M, Llop E, Gomez-Pimpollo L, Fernandez Carrillo C, Rodriguez L, Van Den Brule E, Perello C, Lopez-Gomez M, Abad J, Martinez-Porras JL, et al. Adding branched-chain amino acids to an enhanced standard-of-Care Treatment improves muscle Mass of cirrhotic patients with Sarcopenia: a placebo-controlled trial. Am J Gastroenterol. 2021;116(11):2241–9.CrossRefPubMed
16.
Mohta S, Anand A, Sharma S, Qamar S, Agarwal S, Gunjan D, Singh N, Madhusudhan KS, Pandey RM, Saraya A. Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia. Hepatol Int. 2022;16(3):680–90.CrossRefPubMed
17.
Uojima H, Sakurai S, Hidaka H, Kinbara T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, et al. Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(12):1402–7.CrossRefPubMed
18.
Leurmarnkul W, Meetam P. Properties Testing of the retranslated SF-36 (Thai Version). Thai J Pharm Sci. 2005;29(1–2):69–88.
19.
Wang S, Whitlock R, Xu C, Taneja S, Singh S, Abraldes JG, Burak KW, Bailey RJ, Lai JC, Tandon P. Frailty is associated with increased risk of cirrhosis disease progression and death. Hepatology. 2022;75(3):600–9.CrossRefPubMed
20.
21.
22.
Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, Engelmann C, Zhang P, Jeong JY, van Vugt JLA, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;76(3):588–99.CrossRefPubMed
23.
Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther. 2020;51(1):64–77.CrossRefPubMed
24.
Kitajima Y, Takahashi H, Akiyama T, Murayama K, Iwane S, Kuwashiro T, Tanaka K, Kawazoe S, Ono N, Eguchi T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol. 2018;53(3):427–37.CrossRefPubMed
25.
Singh Tejavath A, Mathur A, Nathiya D, Singh P, Raj P, Suman S, Mundada PR, Atif S, Rai RR, Tomar BS. Impact of branched chain amino acid on muscle Mass, muscle strength, physical performance, combined survival, and maintenance of liver function changes in laboratory and prognostic markers on sarcopenic patients with liver cirrhosis (BCAAS study): a Randomized Clinical Trial. Front Nutr. 2021;8:715795.CrossRefPubMedPubMedCentral
26.
Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, Holman J, Howes N, Haykowsky MJF, Josbeno DA, et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol. 2018;69(5):1164–77.CrossRefPubMed
27.
Duarte-Rojo A, Ruiz-Margain A, Montano-Loza AJ, Macias-Rodriguez RU, Ferrando A, Kim WR. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 2018;24(1):122–39.CrossRefPubMed
28.
Chen HW, Ferrando A, White MG, Dennis RA, Xie J, Pauly M, Park S, Bartter T, Dunn MA, Ruiz-Margain A, et al. Home-Based physical activity and Diet intervention to improve physical function in Advanced Liver Disease: a Randomized Pilot Trial. Dig Dis Sci. 2020;65(11):3350–9.CrossRefPubMed
29.
Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, Saab S, Bolus R, Spiegel BM. Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol. 2009;7(7):793–9.CrossRefPubMed
30.
Kok B, Whitlock R, Ferguson T, James Bailey R, Warren Burak K, Kowalczewski J, Tangri N, Tandon P. Health-Related Quality of Life: a Rapid Predictor of hospitalization in patients with cirrhosis. Am J Gastroenterol. 2020;115(4):575–83.CrossRefPubMed
31.
Hidaka H, Nakazawa T, Kutsukake S, Yamazaki Y, Aoki I, Nakano S, Asaba N, Minamino T, Takada J, Tanaka Y, et al. The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. J Gastroenterol. 2013;48(2):269–76.CrossRefPubMed
32.
Kawamura E, Habu D, Morikawa H, Enomoto M, Kawabe J, Tamori A, Sakaguchi H, Saeki S, Kawada N, Shiomi S. A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl. 2009;15(7):790–7.CrossRefPubMed
33.
Hara N, Iwasa M, Sugimoto R, Mifuji-Moroka R, Yoshikawa K, Terasaka E, Hattori A, Ishidome M, Kobayashi Y, Hasegawa H, et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. Intern Med. 2016;55(8):863–70.CrossRefPubMed
34.
Pirlich M, Schutz T, Spachos T, Ertl S, Weiss ML, Lochs H, Plauth M. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology. 2000;32(6):1208–15.CrossRefPubMed
35.
Ruiz-Margain A, Xie JJ, Roman-Calleja BM, Pauly M, White MG, Chapa-Ibarguengoitia M, Campos-Murguia A, Gonzalez-Regueiro JA, Macias-Rodriguez RU, Duarte-Rojo A. Phase Angle from Bioelectrical Impedance for the Assessment of Sarcopenia in Cirrhosis with or without Ascites. Clin Gastroenterol Hepatol. 2021;19(9):1941–9. e2.CrossRefPubMed
Metadata
Title
Branched-chain amino acids supplementation improves liver frailty index in frail compensated cirrhotic patients: a randomized controlled trial
Authors
Sith Siramolpiwat
Nisakorn Limthanetkul
Bubpha Pornthisarn
Ratha-korn Vilaichone
Soonthorn Chonprasertsuk
Patommatat Bhanthumkomol
Pongjarat Nunanan
Navapan Issariyakulkarn
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Sarcopenia
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02789-1

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue

Research

Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis

Research

Large common bile duct stones in high-risk elderly patients: Immediate endoscopic stone removal or elective stone removal? A single-center retrospective study

Research

Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer

Research

Macrophage polarization toward M1 phenotype in T cell transfer colitis model

Research article

Lower ultra-short-term heart rate variability can predict worse mucosal healing in ulcerative colitis

Research

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits